Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2016', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects - The report assesses Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 9 Therapeutics Development 10 Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview 10 Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis 11 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies 12 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes 13 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies 17 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes 19 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development 20 Ahn-Gook Pharmaceutical Co., Ltd. 20 Cempra, Inc. 21 Daewoong Pharmaceutical Co., Ltd. 22 Eisai Co., Ltd. 23 Ironwood Pharmaceuticals, Inc. 24 Johnson & Johnson 25 RaQualia Pharma Inc. 26 Shire Plc 27 Sucampo Pharmaceuticals, Inc. 28 Vecta Ltd. 29 Wockhardt Limited 30 Yuyu Pharma, Inc. 31 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 (lansoprazole + omeprazole) - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 2-methoxyestradiol prodrug 1 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 cobiprostone - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 DWJ-1367 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 E-3710 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 esomeprazole magnesium - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 G-17DT - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 IW-3718 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 JNJ-26070109 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 netazepide - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 omeprazole - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 pantoprazole - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 revexepride - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 RQ-00000004 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 RQ-00000774 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Small Molecule for Peptic Ulcers - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Small Molecules to Block Proton Pump for Gastrointestinal Disorders - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 tenatoprazole - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 TR-2A - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 YY-DXR - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Recent Pipeline Updates 66 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects 70 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products 73 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones 76 Featured News & Press Releases 76 Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting 76 Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease 76 Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease 77 Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision 78 Mar 29, 2011: RaQualia Pharma Announces Successful Results From Phase I Study Of Acid Pump Antagonist 78 Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare 79 Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 80 Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 80 Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC 80 Dec 05, 2009: Santarus Receives FDA Approval for Immediate-Release Omeprazole 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2016 10 Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Investigation by Universities/Institutes, H1 2016 19 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2016 20 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra, Inc., H1 2016 21 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 22 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co., Ltd., H1 2016 23 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 24 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Johnson & Johnson, H1 2016 25 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc., H1 2016 26 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Shire Plc, H1 2016 27 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 28 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Vecta Ltd., H1 2016 29 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Limited, H1 2016 30 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma, Inc., H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics - Recent Pipeline Updates, H1 2016 66 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2016 70 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..1), H1 2016 71 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..2), H1 2016 72 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2016 73 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..1), H1 2016 74 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..2), H1 2016 75
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.